Gilead Sciences, Inc. (GILD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 79.02 |
| Open | 79.63 |
| Bid | 80.09 x 1100 |
| Ask | 80.10 x 800 |
| Day's Range | 79.47 - 80.84 |
| 52 Week Range | 72.87 - 89.74 |
| Volume | |
| Avg. Volume | 5,773,766 |
| Market Cap | 99.795B |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | 17.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.00 (3.80%) |
| Ex-Dividend Date | Dec 14, 2023 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
Related Research
- Gilead Sciences, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 18,000 employees.RatingFair ValueEconomic Moat13 days agoArgus Research
- Motley Fool
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most technological group of cancer medicines produced to date. Now, drugmakers including Novartis (NYSE: NVS), Gilead Sciences (NASDAQ: GILD), and Bristol Myers Squibb (NYSE: BMY) are on the hot seat, with their patients' well-being and billions of dollars in revenue on the line. The FDA is concerned about chimeric antigen receptor T-cell (CAR T-cell) therapies.
- Simply Wall St.
Four Days Left To Buy Gilead Sciences, Inc. (NASDAQ:GILD) Before The Ex-Dividend Date
Readers hoping to buy Gilead Sciences, Inc. ( NASDAQ:GILD ) for its dividend will need to make their move shortly, as...
- Zacks
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.
